Recognizing early signs of multiple myeloma—fatigue, bone pain, and anemia—can lead to faster diagnosis and better outcomes, says IMF Chief Medica Officer Dr. Joseph Mikhael. In this interview with CURE, Dr. Mikhael discusses how new targeted therapies, immunotherapy approaches like CAR-T cell therapy, and personalized treatment plans are revolutionizing myeloma care. He also emphasizes the power of shared decision-making and strong patient support networks in improving both survival and quality of life. Read the full article to learn how modern medicine is reshaping the future for myeloma patients.